Tratamiento del carcinoma broncogénico de célula no pequeña en estadios precoces / Treatment of non-small cell lung carcinoma in early stages

El tratamiento del carcinoma brongénico es multidisciplinar. Se dispone de diferentes estrategias terapéuticas, siendo la cirugía la que presenta mejores resultados en aquellos pacientes con carcinoma broncogénico en estadios precoces. Otras opciones como la radioterapia estereotáctica quedan relegadas a pacientes con pequeños tumores y mala reserva cardiopulmonar, o a aquellos que rechacen la cirugía. La quimioterapia adyuvante no está justificada en pacientes con enfermedad en estadio i , planteándose doble quimioterapia adyuvante basada en cisplatino tras la cirugía en aquellos con estadios ii y III A (AU)

Treatment of lung carcinoma is multidisciplinary. There are different therapeutic strategies available, although surgery shows the best results in those patients with lung carcinoma in early stages. Other options such as stereotactic radiation therapy are relegated to patients with small tumors and poor cardiopulmonary reserve or to those who reject surgery. Adjuvant chemotherapy is not justified in patients with stage i of the disease and so double adjuvant chemotherapy should be considered. This adjuvant chemotherapy should be based on cisplatin after surgery in those patients with stages ii and IIIA (AU)

[Treatment of non-small cell lung carcinoma in early stages]. / Tratamiento del carcinoma broncogénico de célula no pequeña en estadios precoces.

Treatment of lung carcinoma is multidisciplinary. There are different therapeutic strategies available, although surgery shows the best results in those patients with lung carcinoma in early stages. Other options such as stereotactic radiation therapy are relegated to patients with small tumors and poor cardiopulmonary reserve or to those who reject surgery. Adjuvant chemotherapy is not justified in patients with stage i of the disease and so double adjuvant chemotherapy should be considered. This adjuvant chemotherapy should be based on cisplatin after surgery in those patients with stages ii and IIIA.

Desarrollo de un programa de donación pulmonar en asistolia con «preservación en bitermia» y resultados tras un año de experiencia clínica / Development of a Non-Heart-Beating Lung Donor Program With «Bithermia Preservation», and Results After One Year of Clinical Experience

El número de trasplantes pulmonares que se realizan en España continúa en ascenso, con 235 pacientes trasplantados en 2010. Los programas de donantes en asistolia han contribuido a esta progresión. Nuestra Unidad de Trasplante Pulmonar comenzó su actividad en octubre de 2008, y en estos 3 años se han trasplantado con éxito el 97% de los pacientes intervenidos. Para obtener un mayor número de donantes hemos desarrollado un programa de donación pulmonar en asistolia a partir del programa existente en nuestro hospital. Fue necesario la elaboración de una metodología de preservación multiorgánica (pulmonar, hepática y renal) que hemos denominado «preservación en bitermia». Presentamos la experiencia de su aplicación clínica durante el primer año. Hemos trasplantado 3 pacientes utilizando este tipo de donantes en asistolia. Ninguno de los pacientes desarrolló disfunción primaria del injerto, todos fueron dados de alta, realizan vida activa y sin datos de síndrome de bronquiolitis obliterante (AU)

The number of lung transplantations that are performed in Spain continues to grow, with 235 transplant recipients 2010. Non-heart-beating donations have contributed to this upward progression. Our Lung Transplant Unit began its activity in October 2008 and during these last three years 97% of the transplant interventions performed have been successful. In order to increase the number of donations, we have developed a non-heart-beating donor program as part of the existing organs program in our hospital. In doing so, the development of a multi-organic preservation method (lung, liver and kidney), which we call «Bithermia Preservation», was necessary. This paper presents this methodology as well as the first year of clinical application experience. During this time, 3 patients have been transplanted using such non-heart-beating donations. None of them developed primary graft dysfunction; all the patients have been discharged and lead active lives without any evidence of bronchiolitis obliterans syndrome (AU)

Development of a non-heart-beating lung donor program with «Bithermia Preservation¼, and results after one year of clinical experience.

The number of lung transplantations that are performed in Spain continues to grow, with 235 transplant recipients 2010. Non-heart-beating donations have contributed to this upward progression. Our Lung Transplant Unit began its activity in October 2008 and during these last three years 97% of the transplant interventions performed have been successful. In order to increase the number of donations, we have developed a non-heart-beating donor program as part of the existing organs program in our hospital. In doing so, the development of a multi-organic preservation method (lung, liver and kidney), which we call «Bithermia Preservation¼, was necessary. This paper presents this methodology as well as the first year of clinical application experience. During this time, 3 patients have been transplanted using such non-heart-beating donations. None of them developed primary graft dysfunction; all the patients have been discharged and lead active lives without any evidence of bronchiolitis obliterans syndrome.

Sobreinfestación de un quiste hidatídico pulmonar por Balantidium coli / Superinfection by Balantidium coli of a pulmonary hydatidic cyst

No disponible